CD22 and neoplasm: found that the strategy of radiotherapy followed by targeting CD19, CD20 or CD22 CAR‐T cell treatment is a safer and more effective scheme in treating R/RDLBCL with high tumor load because the radiotherapy may play a role in supplying the CAR‐T cells and resisting CRS by decreasing the local tumor IL‐6 [162, 163].